ArticleBeilstein journal of nanotechnology2019
Enhanced inhibition of influenza virus infection by peptide-noble-metal nanoparticle conjugates.
Article in Beilstein journal of nanotechnology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 51 citations in OpenAlex.
- Silver Nanoparticle-Mediated Antiviral Efficacy against Enveloped Viruses: A Comprehensive Review.Global challenges (Hoboken, NJ) · 2025Review
- Antiviral polysaccharide and antiviral peptide delivering nanomaterials for prevention and treatment of SARS-CoV-2 caused COVID-19 and other viral diseases.Journal of controlled release : official journal of the Controlled Release Society · 2023Review
- Nanomedicine for drug resistant pathogens and COVID-19 using mushroom nanocomposite inspired with bacteriocin - A review.Inorganic chemistry communications · 2023Review
- Targeting Protein-Protein Interfaces with Peptides: The Contribution of Chemical Combinatorial Peptide Library Approaches.International journal of molecular sciences · 2023Review
- Antiviral Peptides in Antimicrobial Surface Coatings-From Current Techniques to Potential Applications.Viruses · 2023Review
- Advanced Plasmonic Nanoparticle-Based Techniques for the Prevention, Detection, and Treatment of Current COVID-19.Plasmonics (Norwell, Mass.) · 2023Review
- Computer Simulation of the Interaction between SARS-CoV-2 Spike Protein and the Surface of Coinage Metals.Langmuir : the ACS journal of surfaces and colloids · 2022Article
- Nanoparticles in clinical trials of COVID-19: An update.International journal of surgery (London, England) · 2022Review
- Metallic Structures: Effective Agents to Fight Pathogenic Microorganisms.International journal of molecular sciences · 2022Review
- Supramolecular assembly of pentamidine and polymeric cyclodextrin bimetallic core-shell nanoarchitectures.Beilstein journal of nanotechnology · 2022Article
- Recent advances on therapeutic potentials of gold and silver nanobiomaterials for human viral diseases.Current research in chemical biology · 2022Review
- Silver Nanoparticles as Potential Antiviral Agents.Pharmaceutics · 2021Review
- Silver nanoparticles as a potential treatment against SARS-CoV-2: A review.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 2021Review
- Metal Nanoparticles: a Promising Treatment for Viral and Arboviral Infections.Biological trace element research · 2021Review
- Nanotechnology-Based Approach to Combat Pandemic COVID 19: A Review.Macromolecular symposia · 2021Article
- Nanotechnology-based antiviral therapeutics.Drug delivery and translational research · 2021Review
- Nanotechnology for virus treatment.Nano today · 2021Review
- Recent Advancement in Nanotechnology-Based Drug Delivery System Against Viral Infections.AAPS PharmSciTech · 2021Review
- Nanomedicine for COVID-19: the role of nanotechnology in the treatment and diagnosis of COVID-19.Emergent materials · 2021Review
- A proposed insight into the anti-viral potential of metallic nanoparticles against novel coronavirus disease-19 (COVID-19).Bulletin of the National Research Centre · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The influenza ("flu") type-A virus is a major medical and veterinary health concern and causes global pandemics. The peptide "FluPep" is an established inhibitor of influenza virus infectivity in model systems. We have explored the potential for noble-metal nanoparticle conjugates of FluPep to enhance its antiviral activity and to determine their potential as a delivery platform for FluPep. FluPep ligand is FluPep extended at its N-terminus with the sequence CVVVTAAA, to allow for its incorporation into a mixed-matrix ligand shell of a peptidol and an alkanethiol ethylene glycol consisting of 70% CVVVTol and 30% HS(CH
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.